Provided by Tiger Trade Technology Pte. Ltd.

Macrogenics

4.02
-0.0800-1.95%
Post-market: 4.020.00000.00%16:20 EDT
Volume:432.52K
Turnover:1.74M
Market Cap:255.86M
PE:-17.55
High:4.08
Open:4.07
Low:3.97
Close:4.10
52wk High:5.08
52wk Low:1.29
Shares:63.65M
Float Shares:57.01M
Volume Ratio:1.01
T/O Rate:0.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2291
EPS(LYR):-1.1815
ROE:-225.85%
ROA:-8.05%
PB:5.97
PE(LYR):-3.40

Loading ...

BRIEF-MacroGenics Q1 Net Income USD -36.8 Million

Reuters
·
May 14

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

GlobeNewswire
·
May 14

Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks

Simply Wall St.
·
May 13

MacroGenics sells GMP manufacturing operations to Bora for $122.5 million upfront payment

Reuters
·
May 12

MacroGenics Inc - to Sell Gmp Manufacturing Operations to Bora

THOMSON REUTERS
·
May 12

MacroGenics to Sell Gmp Manufacturing Operations to Bora Pharmaceuticals

THOMSON REUTERS
·
May 12

MacroGenics Inc - to Enter Supply Arrangement With Bora for Process Development and Drug Substance Production for Its Internal Pipeline Needs

THOMSON REUTERS
·
May 12

MacroGenics Inc: to Receive $122.5 Mln Upfront Payment From Bora Upon Closing

THOMSON REUTERS
·
May 12

MacroGenics trading halted, news pending

TIPRANKS
·
May 12

NASDAQ TRADE HALT HALT NEWS PENDING AT 04:25 PM

Reuters
·
May 12

MacroGenics sells capped Zynyz royalty interest to Sagard for $60 million

Reuters
·
May 04

BRIEF-Macrogenics And Sagard Healthcare Partners Enter Into Expanded Zynyz® Royalty Purchase Agreement

Reuters
·
May 04

MacroGenics Inc - All Royalty Rights Revert to MacroGenics After Sagard Receives 1.7X or 2.0X Investment by September 30, 2032

THOMSON REUTERS
·
May 04

MacroGenics Inc - Receives $60 Mln Upfront, Eligible for up to $20 Mln 2026 Milestone

THOMSON REUTERS
·
May 04

MacroGenics and Sagard Healthcare Partners Enter Into Expanded Zynyz® Royalty Purchase Agreement

THOMSON REUTERS
·
May 04

Macrogenics Is Maintained at Overweight by Barclays

Dow Jones
·
Apr 20

Macrogenics Raised to Buy From Neutral by B. Riley Securities

Dow Jones
·
Apr 11

B. Riley Upgrades MacroGenics to Buy From Neutral, Triples Price Target to $9 From $3

MT Newswires Live
·
Apr 10

MacroGenics upgraded to Buy from Neutral at B. Riley

TIPRANKS
·
Apr 10

FDA Lifts Hold on Macrogenics Gynecological Cancer Treatment Trial

Dow Jones
·
Apr 09